Literature DB >> 23199377

Hemizygous deletion of CTGF/CCN2 does not suffice to prevent fibrosis of the severely injured kidney.

Lucas L Falke1, Amélie Dendooven, Jan Willem Leeuwis, Tri Q Nguyen, Rob J van Geest, Dionne M van der Giezen, Roel Broekhuizen, Karen Lyons, Reinout Stoop, Hans Kemperman, Reinier Schlingemann, Jaap A Joles, Roel Goldschmeding.   

Abstract

BACKGROUND: Connective Tissue Growth Factor (CTGF/CCN2) is an important mediator of kidney fibrosis. Previous observations indicated that attenuation of CCN2 expression sufficed to alleviate early kidney damage. However, little is known about the role of CCN2 in fibrosis of severely damaged and more chronically injured kidneys. Therefore, we examined the effects of CCN2 haploinsufficiency on the progression of renal scarring in long-term STZ-induced diabetic nephropathy, in a more advanced stage of obstructive nephropathy following unilateral ureteric obstruction (UUO), and in severe aristolochic acid (AA)-induced tubulotoxic nephritis.
METHODS: Wild-type (WT, CCN2(+/+)) and hemizygous CCN2(+/-) C57Bl/6 mice were studied. In the diabetes experiment, streptozotocin-injected and control mice were followed for 6 months, with regular blood pressure, glycaemia and albuminuria recordings. In the UUO experiment, the left ureter was obstructed for 14 days with the contralateral kidney serving as control. For the AA experiment, mice were followed for 25 days after 5 intraperitoneal injections with AA and compared to control mice injected with buffer alone. Organs were harvested for histology, mRNA and protein measurements. Collagen content was determined by HPLC and expressed as hydroxyproline/proline ratio.
RESULTS: CCN2 expression was significantly increased in the damaged as compared to control kidneys. In all three models, CCN2 levels in the damaged kidneys of CCN2(+/-) mice averaged about 50% of those in damaged WT kidneys. After 6 months of diabetes, albuminuria was increased 2.5-fold in WT mice, compared to 1.5-fold in CCN2(+/-) mice, mesangial matrix was expanded 5-fold in WT and 4.4-fold in CCN2(+/-) mice and the glomerular basement membrane was thickened 1.3-fold in WT and 1.5-fold in CCN2(+/-) mice (all differences between WT and CCN2(+/-) mice are NS). Tubular damage and interstitial fibrosis scores were also not different between Wt and CCN2(+/-) mice in the diabetes (1.8 vs. 1.7), UUO (2.8 vs. 2.6), and AA (1.4 vs. 1.2) models, as was the case for macrophage influx and collagen content in these three models.
CONCLUSION: Unlike in mild and relatively early STZ-induced diabetic nephropathy, scarring of severely and chronically damaged kidneys is not attenuated by a 50% reduction of CCN2 to (near) normal levels. This suggests that CCN2 is either redundant in severe and chronic kidney disease, or that it is a limiting factor only at subnormal concentrations requiring further reduction by available or emerging therapies to prevent fibrosis of the severely injured kidney.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23199377     DOI: 10.1016/j.matbio.2012.06.002

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  15 in total

1.  Loss of tumour suppressor PTEN expression in renal injury initiates SMAD3- and p53-dependent fibrotic responses.

Authors:  Rohan Samarakoon; Sevann Helo; Amy D Dobberfuhl; Nidah S Khakoo; Lucas Falke; Jessica M Overstreet; Roel Goldschmeding; Paul J Higgins
Journal:  J Pathol       Date:  2015-04-27       Impact factor: 7.996

Review 2.  Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology.

Authors:  Madalina V Nastase; Renato V Iozzo; Liliana Schaefer
Journal:  Biochim Biophys Acta       Date:  2014-02-05

Review 3.  Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease.

Authors:  Helena M Kok; Lucas L Falke; Roel Goldschmeding; Tri Q Nguyen
Journal:  Nat Rev Nephrol       Date:  2014-10-14       Impact factor: 28.314

4.  Connective Tissue Growth Factor Single Nucleotide Polymorphisms in (Familial) Pulmonary Fibrosis and Connective Tissue Disease Associated Interstitial Lung Disease.

Authors:  Dymph Klay; Joanne J van der Vis; Suzan M Roothaan; Tri Q Nguyen; Jan C Grutters; Roel Goldschmeding; Coline H M van Moorsel
Journal:  Lung       Date:  2021-11-23       Impact factor: 2.584

Review 5.  Therapeutic targets for treating fibrotic kidney diseases.

Authors:  So-Young Lee; Sung I Kim; Mary E Choi
Journal:  Transl Res       Date:  2014-08-13       Impact factor: 7.012

6.  A robust, accurate, sensitive LC-MS/MS method to measure indoxyl sulfate, validated for plasma and kidney cells.

Authors:  Sabbir Ahmed; Rolf W Sparidans; Jingyi Lu; Silvia M Mihaila; Karin G F Gerritsen; Rosalinde Masereeuw
Journal:  Biomed Chromatogr       Date:  2022-02-08       Impact factor: 1.911

7.  Blockade of CCN4 attenuates CCl4-induced liver fibrosis.

Authors:  Xiaofei Li; Yongxin Chen; Weiwei Ye; Xingfei Tao; Jinhong Zhu; Shuang Wu; Lianqing Lou
Journal:  Arch Med Sci       Date:  2015-06-19       Impact factor: 3.318

8.  Connective tissue growth factor (CTGF) expression modulates response to high glucose.

Authors:  Leighton R James; Catherine Le; Heather Doherty; Hyung-Suk Kim; Nobuyo Maeda
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

9.  CCN2 reduction mediates protective effects of BMP7 treatment in obstructive nephropathy.

Authors:  Lucas L Falke; Jan Willem Leeuwis; Karen M Lyons; Christine L Mummery; Tri Q Nguyen; Roel Goldschmeding
Journal:  J Cell Commun Signal       Date:  2016-10-20       Impact factor: 5.782

10.  Expression levels of TGF-β1 and CTGF are associated with the severity of Duchenne muscular dystrophy.

Authors:  Yanmin Song; Shuai Yao; Yunhai Liu; Lili Long; Huan Yang; Qiuxiang Li; Jinghui Liang; Xinxin Li; Yuling Lu; Haoran Zhu; Ning Zhang
Journal:  Exp Ther Med       Date:  2017-02-07       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.